With Inlexzo Approval, J&J Is At The Starting Line To Build A $5bn+ Franchise

 
• By Jessica Merrill
  
Inlexzo was approved in a small initial bladder cancer indication (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapy Areas